Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Immunotherapy

Tumour Site

Prostate Cancer

Presenters

Alejo Rodriguez-Vida

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

A. Rodriguez-Vida1, J.P. Maroto Rey2, A. Font Pous3, C. Martin4, B. Mellado5, A. Corbera Lloret6, M. Orrillo Sarmiento6, O. Reig Torras7, R. Querol Ninerola8, L. Cano9, A. Palazon9, J. Alonso9, S. Galtes9, N. Juanpere10, O. Juan11, J. Bellmunt12

Author affiliations

  • 1 Medical Oncology Department, Hospital del Mar, 8003 - Barcelona/ES
  • 2 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 - Barcelona/ES
  • 3 Departamento De Oncologia, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), 08916 - Badalona/ES
  • 4 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08 - Barcelona/ES
  • 5 Medical Oncology Dept., Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 6 Medical Oncology Dept., Hospital del Mar, 8003 - Barcelona/ES
  • 7 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 8 Medical Oncology, Hospital de Mataro - Consorcio Sanitario del Maresme, 8304 - Mataro/ES
  • 9 Medical Oncology Department, Hospital del Mar, 08003 - Barcelona/ES
  • 10 Pathology Department, Hospital del Mar, 08003 - Barcelona/ES
  • 11 Medical Oncology Department, Pivotal Clinical Research Organization, 00 - Madrid/ES
  • 12 Medical Oncology Department, Harvard Medical School, 2115 - Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 631P

Background

Immune checkpoint inhibitors have been approved for various solid tumors. However, their use in castration-resistant prostate cancer (CRPC) is still at an early phase of development.

Methods

Safety and efficacy of PD-L1 inhibitor avelumab plus carboplatin was investigated in a single-arm phase Ib study in patients with metastatic CRPC progressing to at least 1 taxane and 1 androgen receptor inhibitor. Patients received 2 cycles of carboplatin AUC5 followed by 2 cycles of avelumab 10mg/kg plus carboplatin AUC5, and by maintenance avelumab for 2 years. Safety was the primary endpoint. Secondary endpoints included PSA and radiographic responses, progression-free survival (PFS) and overall survival (OS). Germline and somatic mutation analysis was performed in all patients.

Results

26 patients were included. Median age was 70 years (range 55-83), 38.5% patients had visceral metastasis, 42.3% were ECOG PS0 and 57.7% PS1. Patients were heavily pretreated: 76.9% received ≥3 and 42.3% ≥4 treatment lines. Median treatment duration was 8.8 months (range 1.4-20.9) and median follow-up 14.2 months (95% CI 12.7-17.9). Safety profile was acceptable with 80% of patients experiencing AEs of any grade, 69% G3-4 AEs. Most frequent G3-4 AEs were: anemia (15/26, 57.7%) and thrombocytopenia (10/26, 38.4%). Confirmed PSA response rates ≥30% and ≥50% were seen in 15.4% (4/26) and 7.7% (2/26), respectively. Any reduction of PSA was seen in 34.6% of patients. Objective partial response rate in patients with measurable disease was 12.5% (2/16). These 2 responders had both a known HRD deleterious mutation (one BRCA2, one ATM). Disease control rate was 69.2% (18/26). Median radiographic PFS was 6.78 months (95% CI 4.28-9.01) and median OS 10.56 months (95% CI 6.68-NR). At the time of reporting these results, the overall genomic analysis is ongoing.

Conclusions

Avelumab plus carboplatin has an acceptable safety profile. Overall clinical benefit was seen in almost 70% of patients and was associated with a prolonged OS given the heavily pretreated population. A deleterious mutation in an HRD gene was present in the two patients showing a partial radiographic response.

Clinical trial identification

EudraCT 2017-004552-39.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This research was financially supported by Pfizer, as part of an alliance between Pfizer and Merck KGaA, Darmstadt, Germany.

Disclosure

A. Rodriguez-Vida: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: msd; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Takeda. J.P. Maroto Rey: Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: EUSA; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: BMS. A. Font Pous: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Pierre Fabre; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca. C. Martin: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Invited Speaker: Roche. B. Mellado: Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Bayer; Financial Interests, Institutional, Research Grant: Janssen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Sanofi. A. Corbera Lloret: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Janssen. M. Orrillo Sarmiento: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: MSD. O. Reig Torras: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Pzifer. R. Querol Ninerola: Other, Personal, Other: Boheringer Ingelheim; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Merck. N. Juanpere: Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca. O. Juan: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca. J. Bellmunt: Financial Interests, Personal, Invited Speaker: Genentech; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Oncogenex; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Takeda; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.